Bibliography
- Lindstr⊘m JM , SeyboldME, LennonVA, WhittinghamS, DuaneDD: Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. 1975 classical article.Neurology51, 933–939 (1998).
- Romi F , SkeieGO, AarliJA, GilhusNE: Muscle antibodies in subgroups of myasthenia gravis patients.J. Neurol.247, 369–375 (2000).
- Strauss AJL , SeegalBC, HsuKC, Burkholder PM, Nastuk WL, Osserman KE: Immunofluorescence demonstration of a muscle binding, complement-fixing serum globulin fraction in myasthenia gravis. Proc. Soc. Exp. Biol. Med.105, 184–191 (1960).
- Aarli JA , LefvertAK, TonderO: Thymoma-specific antibodies in sera from patients with myasthenia gravis demonstrated by indirect hemagglutination.J. Neuroimmunol.1, 421–427 (1981).
- Romi F , SkeieGO, GilhusNE, AarliJA: Striational antibodies in myasthenia gravis. Reactivity and possible clinical significance.Arch. Neurol.62, 442–446 (2005).
- Aarli JA , StefanssonK, MartonLSG, WollmannRL: Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin.Clin. Exp. Immunol.82, 284–288 (1990).
- Labeit S , KolmererB: Titins: giant proteins in charge of muscle ultrastructure and elasticity.Science270, 293–296 (1995).
- Lange S , XiangF, YakovenkoAet al.: The kinase domain of titin controls muscle gene expression and protein turnover.Science308, 1599–1603 (2005).
- Granzier HL , LabeitS: The giant muscle protein titin is an adjustable molecular spring.Exerc. Sport Sci. Res.34, 50–53 (2006).
- Fürst DO , GautelM: The anatomy of a molecular giant: how the sarcomere cytoskeleton is assembled from immunoglobulin superfamily molecules.J. Mol. Cell. Cardiol.7, 951–959 (1995).
- Gautel M , LakeyA, BarlopwDPet al.: Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin.Neurology43, 1581–1585 (1993).
- Romi F , SkeieGO, AarliJA, GilhusNE: The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies.Arch. Neurol.57, 1596–1600 (2000).
- Fulton AB , IsaacsWB: Titin, a huge, elastic sarcomeric protein with a probable role in morphogenesis.Bioessays13, 157–161 (1991).
- Lübke E , FreiburgA, SkeieGOet al.: Striational autoantibodies in myasthenia gravis patients recognize I-band titin epitopes.J. Neuroimmunol.81, 98–108 (1998).
- Watkins TC , ZelinkaLM, KesicM, AnsevinCF, WalkerGR: Identification of skeletal muscle autoantigens by expression library screening using sera from autoimmune rippling muscle disease (ARMD) patients.J. Cell. Biochem.99, 79–87 (2006).
- Skeie GO : Skeletal muscle titin: physiology and pathophysiology.Cell. Mol. Life Sci.57, 1570–1576 (2000).
- Somnier FE , SkeieGO, AarliJA, Trojaborg W:EMG evidence of myopathy and the occurrence of titin antibodies in patients with myasthenia gravis. Eur. J. Neurol.6, 555–563 (1999).
- Mygland Å, Tysnes OB, Matre R, Volpe P, Aarli JA, Gilhus NE: Ryanodine receptor autoantibodies in myasthenia gravis patients with thymoma. Ann. Neurol.32, 589–591 (1992).
- Mygland A , TysnesOB, AarliJA, MatreR, GilhusNE: IgG subclass distribution of ryanodine receptor autoantibodies in patients with myasthenia gravis and thymoma.J. Autoimmun.4, 507–515 (1993).
- Skeie GO , LundePK, SejerstedOM, MyglandA, AarliJA, GilhusNE: Autoimmunity against the ryanodine receptor in myasthenia gravis.Acta Physiol. Scand.171, 379–384 (2001).
- Nakata M , KuwabaraS, KawaguchiNet al.: Is excitation–contraction coupling impaired in myasthenia gravis?Clin. Neurophysiol.118, 1144–1148 (2007).
- Myking AO , SkeieGO, VarhaugJE, AndersenKS, GilhusNE, AarliJA: The histomorphology of the thymus in late onset, non-thymoma myasthenia gravis.Eur. J. Neurol.5, 401–405 (1998).
- Suzuki S , UtsugisawaK, Naganeet al.: Classification of myasthenia gravis based on autoantibody status. Arch. Neurol.64, 1121–1124 (2007).
- Li YF , ZhangJB, CuiLY: Serum anti-titin antibody in patients with myasthenia gravis.Zhongguo Yi Xue Ke Xue Yuan Xue Bao.25, 725–727 (2003).
- Voltz R , AlbrichW, HohlfeldRet al.: Anti-titin antibodies are not associated with a specific thymoma histology.J. Neurol. Neurosurg. Psychiatry74, 282 (2003).
- Voltz RD , AlbrichWC, NägeleAet al.: Paraneoplastic myasthenia gravis: detection of anti-MGT30 (titin) antibodies predicts thymic epithelial tumor.Neurology49, 1454–1457 (1997).
- Agius M , RichmanD, FaircloughR, AarliJA, GilhusNE, RomiF: Three forms of immune myasthenia.Ann. NY Acad. Sci.998, 453–456 (2003).
- Romi F , AarliJA, GilhusNE: Myasthenia gravis patients with ryanodine receptor antibodies have distinct clinical features.Eur. J. Neurol.14, 617–620 (2007).
- Mygland Å, Vincent A, Newsom-Davis J et al.: Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia. Arch. Neurol.57, 527–531 (2000)
- Oosterhuis HJGH , LimburgPC, Hummel-TappelE: Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients.J. Neurol. Sci.58, 371–385 (1983).
- Mygland Å, Aarli JA, Matre R, Gilhus NE: Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis.J. Neurol. Neurosurg. Psychiatry.57, 843–846 (1994).
- Romi F , SkeieGO, VedelerC, AarliJA, ZorzoF, GilhusNE: Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. A study of IgG subclasses and clinical correlations.J. Neuroimmunol.111, 169–176 (2000).
- Romi F , KristoffersenEK, AarliJA, GilhusNE: The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo.J. Neuroimmunol.158, 191–194 (2005).
- Feltkamp TE , van den Berg-Loonen PM, Nijenhuis LEet al.: Myasthenia gravis, autoantibodies, and HL-A antigens. Br. Med. J.1, 131–133 (1974).
- Compston DAS , VincentA, Newsom-DavisJ, BatchelorJR: Clinical, pathological, HLA-antigen and immunological evidence for disease heterogeneity in myasthenia gravis.Brain103, 579–601 (1980).
- Giraud M , BeaurainG, YamamotoAMet al.: Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology57, 1555–1560 (2001).
- Saruhan-Direskeneli G , KiliçA, ParmanYet al.: HLA-DQ polymorphism in Turkish patients with myasthenia gravis. Hum. Immunol.67, 352–358 (2006).
- Gilhus NE , AarliJA, ChristenssonB, Matre R: Rabbit antiserum to a citric acid extract of human skeletal muscle staining thymomas from myasthenia gravis patients. J. Neuroimmunol.7, 55–64 (1984).
- Dardenne M , SavinoW, BachJF: Thymomatous epithelial cells and skeletal muscle share a common epitope defined by a monoclonal antibody.Am. J. Pathol.126, 194–198 (1987).
- Skeie GO , FreiburgA: Titin transcripts in thymomas.Ann. NY Acad. Sci.841, 422–426 (1998).
- Romi F , B⊘L, SkeieGOet al.: Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules.J. Neuroimmunol.128, 82–89 (2002).
- Buckley C , Newsom-DavisJ, WillcoxN, VincentA: Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?Neurology57, 1579–1582 (2001).
- Baggi F , AndreettaF, AntozziCet al.: Anti-titin and antiryanodine receptor antibodies in myasthenia gravis patients with thymoma.Ann. NY Acad. Sci.841, 538–541 (1998).
- Yamamoto AM , GajdosP, EymardBet al.: Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients.Arch. Neurol.58, 885–890 (2001).
- Chen XJ , QiaoJ, XiaoBG, LuCZ: The significance of titin antibodies in myasthenia gravis – correlation with thymoma and severity of myasthenia gravis.J. Neurol.251, 1006–1011 (2004).